Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 6, 2009, Pages 805-811

  Ghazi, Mirieme ^a   Roux, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

aromatase inhibitors; bisphosphonates; breast cancer; denosumab; fractures; hormonal deprivation therapy; osteoporosis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; DENOSUMAB; ESTRADIOL; EXEMESTANE; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; PARATHYROID HORMONE DERIVATIVE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE FRAGILITY; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; FRACTURE; FRACTURE REDUCTION; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SYNTHESIS; HUMAN; OSTEOLYSIS; PATIENT CARE PLANNING; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VERTEBRA FRACTURE;

AROMATASE INHIBITORS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 71749092293     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.09.003     Document Type: Review

References (25)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2006 56 (2006) 106-130
2. American Cancer Society. Breast cancer facts & figures 2005-2006 (2005), American Cancer Society Inc, Atlanta (GA)
3. Chen S., Ye J., Kijima I., Kinoshita Y., and Zhou D. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol 95 (2005) 17-23
4. Bruggemeier R.W., Hackett J.C., and Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26 (2005) 331-345
5. Cummings S.R., Browner W.S., Bauer D., Stone K., Ensrud K., Jamal S., and Ettinger B. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339 11 (1998 Sep 10) 733-738
6. Oz O.K., Hirasawa g L.J., et al. Bone phenotype of the aromatase deficient mouse. Journal of Steroid Biochemistry & Molecular Biology 79 (2001) 49-59
7. Miyaura C., Toda K., InadaM O.T., Matsumoto C., Okada T., et al. Sex- and age-related response to aromatase deficiency in bone. Bioch Biophys Res Com 280 (2001) 1062-1068
8. Baum M. ATAC Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
9. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
10. Locker G., and Eastell R. The time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial. Proc Am Soc Clin Oncol 22 (2003) 25
11. Eastell R., Hannon R.A., Cuzick J., et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21 (2006) 1215-1223
12. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 26 (2008) 1051-1058
13. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
14. Perez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24 (2006) 3629-3635
15. Coates A.S., Keshaviah A., Thurlimann B., et al. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: update of Study BIG 1-98. J Clin Oncol 25 (2007) 486-492
16. Rabaglio M., Sun Z., Price K.N., et al. Bone fractures among postmenopausal patients with endocrin-responsive early breast cancer with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol (2009) Epub ahead
17. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
18. Coleman R.E., Banks L.M., Girgis S.I., Kilburn L.S., et al. Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
19. Lønning P.E., Geisler J., Krag L.E., Erikstein B., Bremnes Y., Hagen A.I., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone iomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 (2005) 5126-5137
20. Camacho P.M., Dayal A.S., Diaz J.L., Nabhan F.A., Agarwal M., Norton J.G., et al. Prevalence of secondary causes of bone loss among breast cancer patients with ostepenia and osteoporosis. J Clin Oncol 26 33 (2008 Nov 20) 5380-5385
21. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
22. Gnant M.F., Mlineritsch B., Luschin-EbengreuthG, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25 (2007) 820-828
23. Eastell R., Van Poznak C., Hannon R., Clack G., et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month results. J Bone Miner Res 22 suppl 1. (2007) S113
24. Confavreux C.B., Fontana A., Jp F., et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41 (2007) 346-352
25. Ellis G.K., Bone H.G., Chlebowski R., Paul D., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26 30 (2008) 4875-4882